Barclays analyst Leon Wang lowered the firm’s price target on Rapt Therapeutics to $13 from $35 and keeps an Overweight rating on the shares after the company’s lead asset zelnecirnon was placed on clinical hold by the FDA due to a single severe adverse event of liver failure in the Phase 2b study in atopic dermatitis. The analyst thinks the signal is more due to unlucky enrollment of a challenging patient but expects new questions on safety and timeline on top of existing questions to drag on shares until we have more details.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RAPT:
- RAPT Therapeutics Hit by FDA Clinical Trial Hold
- RAPT Therapeutics (NASDAQ:RAPT) Crashes 60% after FDA Places Clinical Hold
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- UPS upgraded, Nike downgraded: Wall Street’s top analyst calls
- Rapt Therapeutics initiated with an Outperform at Evercore ISI